ENZO BIOCHEM INC Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q2 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Enzo Biochem Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2011 to Q3 2024.
  • Enzo Biochem Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending October 31, 2024 was $3.84M, a 8.11% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $3.84M -$339K -8.11% Oct 31, 2024 10-Q 2024-12-16
Q2 2024 $3.99M -$820K -17.1% Jul 31, 2024 10-Q 2024-12-16
Q1 2024 $3.94M -$5.7M -59.2% Apr 30, 2024 10-Q 2024-06-13
Q4 2023 $5.12M -$5.75M -52.9% Jan 31, 2024 10-Q 2024-03-13
Q3 2023 $4.18M -$7.33M -63.7% Oct 31, 2023 10-Q 2023-12-15
Q2 2023 $4.81M +$46K +0.97% Jul 31, 2023 10-K 2024-10-29
Q1 2023 $9.64M -$2.13M -18.1% Apr 30, 2023 10-Q 2023-06-14
Q4 2022 $10.9M -$4.45M -29.1% Jan 31, 2023 10-Q 2023-03-20
Q3 2022 $11.5M +$183K +1.62% Oct 31, 2022 10-Q 2022-12-12
Q2 2022 $4.76M -$5.44M -53.3% Jul 31, 2022 10-K 2023-11-03
Q1 2022 $11.8M +$286K +2.49% Apr 30, 2022 10-Q 2022-06-09
Q4 2021 $15.3M +$3.22M +26.6% Jan 31, 2022 10-Q 2022-03-14
Q3 2021 $11.3M -$719K -5.97% Oct 31, 2021 10-Q 2021-12-15
Q2 2021 $10.2M +$1.06M +11.6% Jul 31, 2021 10-K 2022-10-14
Q1 2021 $11.5M +$4.66M +68.3% Apr 30, 2021 10-Q 2021-06-11
Q4 2020 $12.1M +$3.18M +35.7% Jan 31, 2021 10-Q 2021-03-16
Q3 2020 $12.1M +$2.17M +22% Oct 31, 2020 10-Q 2020-12-11
Q2 2020 $9.14M -$1.6M -14.9% Jul 31, 2020 10-K 2021-10-12
Q1 2020 $6.82M -$4.62M -40.4% Apr 30, 2020 10-Q 2020-06-09
Q4 2019 $8.91M -$2.75M -23.6% Jan 31, 2020 10-Q 2020-03-06
Q3 2019 $9.88M -$2.96M -23.1% Oct 31, 2019 10-Q 2019-12-10
Q2 2019 $10.7M -$2.41M -18.3% Jul 31, 2019 10-K 2020-10-19
Q1 2019 $11.4M -$2.97M -20.6% Apr 30, 2019 10-Q 2019-06-10
Q4 2018 $11.7M -$3.31M -22.1% Jan 31, 2019 10-Q 2019-03-11
Q3 2018 $12.8M -$1.61M -11.1% Oct 31, 2018 10-Q 2018-12-10
Q2 2018 $13.1M -$2.03M -13.4% Jul 31, 2018 10-K 2020-10-19
Q1 2018 $14.4M -$1.4M -8.85% Apr 30, 2018 10-Q 2018-06-11
Q4 2017 $15M -$378K -2.46% Jan 31, 2018 10-Q 2018-03-12
Q3 2017 $14.4M +$386K +2.75% Oct 31, 2017 10-Q 2017-12-07
Q2 2017 $15.2M +$588K +4.03% Jul 31, 2017 10-K 2018-10-15
Q1 2017 $15.8M +$1.81M +12.9% Apr 30, 2017 10-Q 2017-06-08
Q4 2016 $15.4M +$2.48M +19.2% Jan 31, 2017 10-Q 2017-03-13
Q3 2016 $14.1M +$1.29M +10.1% Oct 31, 2016 10-Q 2016-12-08
Q2 2016 $14.6M +$2.48M +20.5% Jul 31, 2016 10-K 2017-09-27
Q1 2016 $14M +$2.39M +20.6% Apr 30, 2016 10-Q 2016-06-08
Q4 2015 $12.9M +$1.08M +9.17% Jan 31, 2016 10-Q 2016-03-09
Q3 2015 $12.8M +$384K +3.1% Oct 31, 2015 10-Q 2015-12-08
Q2 2015 $12.1M -$361K -2.9% Jul 31, 2015 10-K 2016-10-13
Q1 2015 $11.6M -$702K -5.7% Apr 30, 2015 10-Q 2015-06-09
Q4 2014 $11.8M -$60K -0.51% Jan 31, 2015 10-Q 2015-03-12
Q3 2014 $12.4M -$1.34M -9.75% Oct 31, 2014 10-Q 2014-12-09
Q2 2014 $12.5M +$182K +1.48% Jul 31, 2014 10-K 2015-10-13
Q1 2014 $12.3M -$873K -6.62% Apr 30, 2014 10-Q 2014-06-09
Q4 2013 $11.9M -$725K -5.76% Jan 31, 2014 10-Q 2014-03-11
Q3 2013 $13.7M -$286K -2.04% Oct 31, 2013 10-Q 2013-12-10
Q2 2013 $12.3M -$1.85M -13.1% Jul 31, 2013 10-K 2014-10-09
Q1 2013 $13.2M -$703K -5.06% Apr 30, 2013 10-Q 2013-06-10
Q4 2012 $12.6M -$824K -6.15% Jan 31, 2013 10-Q 2013-03-12
Q3 2012 $14M -$668K -4.55% Oct 31, 2012 10-Q 2012-12-10
Q2 2012 $14.1M -$1.11M -7.28% Jul 31, 2012 10-K 2013-10-15
Q1 2012 $13.9M Apr 30, 2012 10-Q 2012-06-11
Q4 2011 $13.4M Jan 31, 2012 10-Q 2012-03-12
Q3 2011 $14.7M Oct 31, 2011 10-Q 2011-12-12
Q2 2011 $15.2M Jul 31, 2011 10-K 2012-10-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.